scispace - formally typeset
D

Dan L. Longo

Researcher at Harvard University

Publications -  730
Citations -  59268

Dan L. Longo is an academic researcher from Harvard University. The author has contributed to research in topics: Antigen & Immune system. The author has an hindex of 125, co-authored 697 publications receiving 56085 citations. Previous affiliations of Dan L. Longo include University of Nebraska Omaha & Yale Cancer Center.

Papers
More filters
Journal ArticleDOI

T-cell specificity for H-2 and Ir gene phenotype correlates with the phenotype of thymic antigen-presenting cells.

TL;DR: Examining the turnover of APCs in the thymuses of F1→parent (P) radiation-induced bone marrow chimaeras found that APCs of donor phenotype appear at about 2 months after reconstitution, suggesting that cells from the bone marrow can influence thymic-directed T-cell differentiation.
Journal ArticleDOI

Increased Circulating Nitrogen Oxides After Human Tumor Immunotherapy: Correlation With Toxic Hemodynamic Changes

TL;DR: It is proposed that mediated induction of .N = O synthase enzyme leads to progressive increases in .N + O production which produces clinically significant hypotension, which could contribute to better management of toxic side effects seen in IL-2 cancer therapies.
Journal ArticleDOI

The polo-like kinase PLK-1 is required for nuclear envelope breakdown and the completion of meiosis in Caenorhabditis elegans.

TL;DR: The Polo‐like kinases are key regulatory molecules required during the cell cycle for the successful completion of mitosis and disruption of PLK‐1 expression by RNA‐mediated interference (RNAi) disrupts normal oocyte and embryonic development.
Journal Article

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

TL;DR: The ability of bryostatin 1 to inhibit the in vitro growth and in vivo development of a panel of four murine tumors of diverse tissue origins and the observation that five of a Panel of six human B-cell lymphoma cell lines were sensitive to the growth inhibitory effects of bRYostatin in vitro suggest that brystatin may be effective in treating lymphoid malignancies in humans.